Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 13/20 | 0.57 |
| ▸ | NPY1R | P25929 | 8/20 | 0.57 |
| ▸ | NPY2R | P49146 | 6/20 | 0.57 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | TFPI | P10646 | 1/20 | 0.51 |
| ▸ | EIF4E | P06730 | 1/20 | 0.50 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.50 |
| ▸ | VIPR2 | P41587 | 3/20 | 0.50 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30143658 | 0.94 | NPY4R (0.63) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30608889 | 0.94 | NPY4R (0.63) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL7119652 | 0.94 | NPY4R (0.63) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL7119638 | 0.94 | NPY4R (0.63) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29625340 | 0.94 | NPY4R (0.63) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29641074 | 0.94 | NPY4R (0.63) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29628209 | 0.94 | NPY4R (0.52) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29461992 | 0.93 | NPY4R (0.63) | NPY4RNPY1RNPY2RNPY5RTFPI | |
| SCHEMBL29540161 | 0.92 | NPY4R (0.66) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29628241 | 0.92 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276116-A1 | METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION | TUFTS MEDICAL CENTER, INC. | 2025-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276116-A1 | METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION | TNNI3, TNNT2, MB | NPY4R 4783/4885NPY1R 4818/4885NPY2R 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.